Spotlight On... What are the big events to look for next year?; Teva is recalling blood pressure med; AAIPharma expands facility; and more...

Novartis' ($NVS) Sandoz unit was the first to get a biosimilar approved in the U.S. with Zarxio, its copy of Amgen's ($AMGN) Neupogen, setting off what will be a significant development for the U.S. market as more copies of expensive biologics test the market. Many companies have built facilities with biosimilars in mind. But there were other significant events in 2015, huge M&A deals, and the ongoing uproar from consumers, payers, physicians and lawmakers over how drugmakers have been testing the limits drug pricing. Read about all of the most important developments of the year in FiercePharma. Report

> Teva ($TEVA) is recalling 3,536 bottles of its generic of irbesartan and Hydrochlorothiazide tablets, a generic of Bristol-Myers Squibb's ($BMY) blood pressure medication Avalide over labeling problems. Report

> North Carolina-based AAIPharma Services Corp./Cambridge Major Laboratories, Inc. says it has added new capabilities and capacity for oral solid manufacturing at its Wilmington, NC, facility. Release

> Codexis has extended its deal with Merck & Co. ($MRK) to supply a proprietary enzyme used in the manufacturing process for sitagliptin, the API in Merck's diabetes drug Januvia. Release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.